ArticleBMJ paediatrics open2026
High-intensity treatment is common at the end of life among children and young people who died of cancer: a retrospective cohort study.
Article in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnnually, approximately 500 children and young people (aged <25 years) with cancer die in England. Little is known about the intensity of their end-of-life care.
aimThe primary aim of this study was to establish the prevalence of high-intensity treatment at the end of life in England and assess the relationship between high-intensity treatment and palliative care integration in main cancer treatment centres. The secondary aim was to assess the relationship between palliative care integration and place of death.
designRetrospective, national full-population cohort study. SETTING/
participantsEnglish Cancer Registry data with linked hospitalisation, treatment and intensive care data were used to define a cohort aged <25 years who died in 2012-2020 and post-cancer diagnosis. High-intensity treatment was defined as any intravenous chemotherapy within 14 days of death or multiple hospitalisations, emergency department visits or any intensive care unit admission within 30 days of death. High-intensity treatment prevalence at the end of life and place of death were summarised by demographics, cancer type, main treatment centre and centre-level integration of palliative care. Logistic regression models explored associations with high-intensity treatment.
results2208 (52%) of the cohort (n=4247) had high-intensity treatments at the end of life and 1911 (45%) died in hospital. High-intensity treatment prevalence varied by age at death and cancer type. There was no evidence of health inequalities in treatments, but minority ethnic groups and those living in more deprived areas had greater odds of dying in hospital.
conclusionsHigh-intensity treatment is common at the end of life among children and young people with cancer; however, its appropriateness is difficult to evaluate. Nevertheless, no evidence of health inequalities was noted, and hospital deaths remain most common.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.